Upadacitinib 30 mg tops JAK inhibitors for moderate-to-severe atopic dermatitis in network meta-analysis
Upadacitinib Shows Highest Efficacy for Moderate to Severe Atopic Dermatitis
A systematic review and network meta-analysis of 9 RCTs (4261 adults) found upadacitinib 30 mg had the highest efficacy for EASI-75, IGA-AD …
A review of data from over 4,000 patients suggests upadacitinib may be the most effective oral treatment among several JAK inhibitors for se…
EV-associated proteins and miRNAs provide high diagnostic accuracy for Lichen Planus and Oral Lichen Planus
New markers show promise for diagnosing Lichen Planus cases
This meta-analysis evaluates the diagnostic utility of extracellular vesicle (EV) associated miRNA and protein biomarkers in patients with L…
Specific proteins and genetic markers could help doctors more accurately identify and track the progression of Lichen Planus.
FDA Approves Skyrizi (risankizumab) for Ulcerative Colitis in Adults
FDA approves Skyrizi for adults with moderate to severe ulcerative colitis.
The FDA approved Skyrizi (risankizumab) for moderately to severely active ulcerative colitis in adults. The recommended induction dosage is …
The FDA approved Skyrizi (risankizumab) for adults with moderate to severe ulcerative colitis. It is given as an IV infusion at first, then …
FDA Approves Skyrizi (risankizumab) for Ulcerative Colitis in Adults
FDA approves Skyrizi for ulcerative colitis, a new treatment option.
The FDA approved Skyrizi (risankizumab) for moderately to severely active ulcerative colitis in adults. The approval adds to existing indica…
The FDA approved Skyrizi (risankizumab) for adults with moderate to severe ulcerative colitis. It is given as an IV infusion at first, then …
FDA Approves Absorica LD (isotretinoin) for Severe Recalcitrant Nodular Acne
FDA approves new acne drug Absorica LD for severe nodular acne.
FDA approved Absorica LD (isotretinoin) for severe recalcitrant nodular acne in non-pregnant patients aged 12 and older. It is reserved for …
The FDA approved Absorica LD (isotretinoin) for severe nodular acne in patients 12 and older. It is for those who have not improved with oth…
FDA Approves Absorica (isotretinoin) for Severe Recalcitrant Nodular Acne
FDA approves new acne drug Absorica for severe cases
The FDA approved Absorica (isotretinoin) for severe recalcitrant nodular acne in non-pregnant patients 12 years and older. It is reserved fo…
The FDA approved Absorica (isotretinoin) for severe nodular acne in patients 12 and older. It is for those who have not improved with other …
Nemolizumab Q4W improves IGA success maintenance by 11.8% over withdrawal in atopic dermatitis
Trial shows nemolizumab maintains skin results for atopic dermatitis
This Phase 3 randomized controlled trial evaluated nemolizumab in 507 adolescents and adults with moderate-to-severe atopic dermatitis who w…
A new trial found that nemolizumab helps maintain clear skin and reduce itching for adults and teens with moderate to severe atopic dermatit…
SSGJ-608 achieves 92.7% to 95.1% PASI75 response in moderate-to-severe plaque psoriasis
New injection shows promise for moderate to severe plaque psoriasis
This phase 3 randomized trial in 770 patients with moderate-to-severe plaque psoriasis found that SSGJ-608 (80mg every 2 weeks or 160mg ever…
A new injectable treatment showed high success rates in clearing skin and improving appearance for people with plaque psoriasis.
Operating room nurses describe critical trauma management challenges and teamwork dynamics in a qualitative review
Nurses share how trauma care shapes their daily work and personal lives
Fifteen experienced trauma nurses shared their lived experiences managing critical multiple injuries in a tertiary Hunan hospital. Their nar…
Fifteen experienced nurses describe the professional challenges, teamwork dynamics, and stress they face while managing critical trauma case…
FDA Approves Tremfya (guselkumab) for Ulcerative Colitis and Crohn's Disease
FDA approves Tremfya for ulcerative colitis and Crohn's disease.
The FDA approved Tremfya (guselkumab) for adults with moderately to severely active ulcerative colitis and Crohn's disease. The approval exp…
The FDA approved Tremfya (guselkumab) for adults with moderate to severe ulcerative colitis or Crohn's disease. It is the first drug of its …
Early preterm birth linked to lower atopic dermatitis risk in large meta-analysis
Preterm birth linked to lower allergy risk in children
A meta-analysis of observational studies involving over 5 million children found that early preterm birth was associated with a reduced risk…
Babies born early may have lower odds of developing eczema and hay fever, a large analysis finds.
High-certainty evidence suggests weight-loss interventions improve psoriasis severity and quality of life in adults
Weight loss linked to better psoriasis severity and quality of life
This systematic review and meta-analysis evaluated weight-loss interventions versus usual care or lower-intensity interventions in adults wi…
A review of 1,145 adults with psoriasis found weight-loss interventions improved skin severity and quality of life more than usual care.